Affinage

PTPRG

Receptor-type tyrosine-protein phosphatase gamma · UniProt P23470

Length
1445 aa
Mass
162.0 kDa
Annotated
2026-06-10
47 papers in source corpus 16 papers cited in narrative 16 extracted findings
Cross-family judge faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PTPRG is a receptor-type protein tyrosine phosphatase that functions broadly as a negative regulator of receptor tyrosine kinase signaling and, in most contexts, as a tumor suppressor (PMID:20651337, PMID:8453613). Its catalytic activity resides in a phosphatase domain whose C1060 active-site cysteine is essential, and it auto-dephosphorylates at Y1307 within its D2 domain (PMID:23029056). At the plasma membrane and within cholesterol-rich lipid domains it directly dephosphorylates activated receptor tyrosine kinases, including FGFR1 in osteosarcoma (PMID:29371290), EGFR at Y1068/Y1086 in nasopharyngeal carcinoma (PMID:25970784), and AXL when AXL is recruited to lipid domains through the GPI-anchored partner OPCML (PMID:29907679); through these substrates it suppresses PI3K/Akt and RAS/ERK signaling, restraining proliferation, angiogenesis, migration, and invasion (PMID:29907679, PMID:25970784, PMID:20651337, PMID:24496747). PTPRG also dampens BCR-ABL1 signaling and modulates nilotinib response in CML (PMID:29507701). Its extracellular carbonic anhydrase-like domain mediates direct, structurally defined binding to contactins CNTN3-6 via their N-terminal Ig repeats (PMID:20133774, PMID:23519440), and in endothelial cells of resistance arteries the protein acts as an HCO3−-sensor that couples bicarbonate sensing to endothelium-dependent vasorelaxation, cerebral perfusion, and blood pressure control (PMID:32955439). PTPRG expression is silenced or attenuated through promoter and intronic CpG methylation and by miR-19b targeting of its 3'-UTR (PMID:24496747, PMID:27602768, PMID:21150880). In contrast to its solid-tumor suppressor role, PTPRG supports survival of malignant plasma cells in multiple myeloma (PMID:41050668).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1993 Medium

    Established PTPRG as a candidate tumor suppressor by showing biallelic inactivation of the locus in a transformed cell line.

    Evidence RT-PCR, genomic PCR, and deletion-boundary sequencing in mouse L-cells

    PMID:8453613

    Open questions at the time
    • Did not define the phosphatase substrates or signaling pathways PTPRG restrains
    • Deletion within the carbonic anhydrase-like domain; functional consequence for catalysis not tested
  2. 2010 High

    Defined the structural basis of PTPRG's extracellular adhesion function, showing its carbonic anhydrase-like domain selectively binds contactins CNTN3-6.

    Evidence X-ray crystallography of PTPRG CA-like domain alone and in complex with CNTN4, plus direct binding assays

    PMID:20133774

    Open questions at the time
    • Functional downstream consequence of contactin binding not resolved
    • Did not connect adhesion to phosphatase signaling output
  3. 2010 Medium

    Linked PTPRG re-expression to tumor suppression through cell-cycle arrest and ERK pathway attenuation.

    Evidence PTPRG overexpression in MCF-7 breast cancer cells, xenografts, and western blots for p21/p27 and ERK1/2

    PMID:20651337

    Open questions at the time
    • Did not identify the direct RTK substrate upstream of ERK in this system
    • Mechanism by which PTPRG raises p21/p27 unresolved
  4. 2012 High

    Demonstrated PTPRG is an active tyrosine phosphatase and mapped an intramolecular auto-dephosphorylation event, providing the catalytic ground truth for its signaling roles.

    Evidence In vitro phosphatase assays, active-site (C1060S) and substrate-trapping (D1028A) mutagenesis, and knock-in/knockdown mouse behavioral models

    PMID:23029056

    Open questions at the time
    • Physiological substrates dephosphorylated in neurons not identified
    • Functional role of Y1307 auto-dephosphorylation in vivo unclear
  5. 2010 Medium

    Showed that PTPRG intronic methylation acts non-canonically by displacing the CTCF insulator rather than simply silencing expression.

    Evidence CpG island microarray, bisulfite sequencing, and CTCF ChIP in colorectal cancer

    PMID:21150880

    Open questions at the time
    • Downstream genes affected by altered CTCF looping not defined
    • Did not link to PTPRG phosphatase activity
  6. 2014 Medium

    Positioned PTPRG as a direct negative regulator of RAS/ERK and explained its silencing through RREB1/methylation-controlled transcription in leukemia.

    Evidence ERK dephosphorylation in 293 cells, genome-wide methylation profiling, and RREB1 ChIP at the PTPRG promoter in childhood ALL

    PMID:24496747

    Open questions at the time
    • Direct RTK substrate upstream of RAS/ERK not identified
    • Cooperation with RAS mutations correlative
  7. 2015 Medium

    Identified EGFR as a direct PTPRG substrate and connected dephosphorylation to suppression of pro-angiogenic/pro-invasive output.

    Evidence Co-IP, phospho-site-specific western blot, Akt knockdown, and in vitro/in vivo tumor models in nasopharyngeal carcinoma

    PMID:25970784

    Open questions at the time
    • Single-lab Co-IP for interaction
    • Whether EGFR dephosphorylation occurs directly or via an intermediate not fully resolved
  8. 2016 Medium

    Established post-transcriptional control of PTPRG by miR-19b, adding a regulatory layer to its loss in cancer.

    Evidence miR-19b gain/loss of function, 3'-UTR luciferase reporter, and phenotypic assays in breast cancer lines

    PMID:27602768

    Open questions at the time
    • In vivo relevance of the miR-19b–PTPRG axis not tested
    • Downstream signaling not mapped
  9. 2018 High

    Demonstrated direct dephosphorylation of FGFR1 by PTPRG at the membrane, showing its loss confers RTK inhibitor resistance.

    Evidence BioID-MS, Co-IP, colocalization, in vitro dephosphorylation, and knockdown phenotypes in osteosarcoma cells

    PMID:29371290

    Open questions at the time
    • Site-specific FGFR1 residues dephosphorylated not detailed
    • Generality across FGFR family members untested
  10. 2018 High

    Defined a lipid-domain-restricted mechanism whereby OPCML recruits AXL to PTPRG for dephosphorylation, blocking RTK transactivation and EMT.

    Evidence Co-IP, lipid domain fractionation, phosphatase assays, OPCML/PTPRG knockdown, and in vitro/in vivo ovarian cancer models

    PMID:29907679

    Open questions at the time
    • Stoichiometry and dynamics of the OPCML-AXL-PTPRG assembly not resolved
  11. 2018 Medium

    Extended PTPRG's RTK-suppressor role to oncogenic fusion kinase signaling and drug sensitivity in CML.

    Evidence CRISPR/Cas9 knockout and overexpression with BCR-ABL1 signaling and nilotinib response readouts in CML lines

    PMID:29507701

    Open questions at the time
    • Whether PTPRG dephosphorylates BCR-ABL1 directly not established
    • Clinical correlation absent
  12. 2020 High

    Revealed a non-tumor physiological function: PTPRG acts as an endothelial HCO3−-sensor controlling vascular tone and perfusion.

    Evidence Knockout mice with Ca2+ imaging, myography, cerebral perfusion, and blood pressure measurements in resistance arteries

    PMID:32955439

    Open questions at the time
    • Molecular link between HCO3− sensing and phosphatase activity not defined
    • Substrate dephosphorylated during bicarbonate sensing unknown
  13. 2024 Medium

    Implicated PTPRG in neurodegeneration by linking it to VIRMA-dependent m6A control of mitophagy.

    Evidence scRNA-seq, spatial transcriptomics, Co-IP in mouse brain, and 5xFAD model

    PMID:38325728

    Open questions at the time
    • VIRMA → PRKN → mitophagy chain relies largely on sequencing/computational inference
    • Whether PTPRG phosphatase activity is required for VIRMA regulation untested
  14. 2025 Medium

    Identified PTPRG as a negative regulator of sensory axonal regeneration.

    Evidence siRNA knockdown with neurite outgrowth/regeneration assays and RNA-seq in DRG neurons and explants

    PMID:41323734

    Open questions at the time
    • Substrate and signaling pathway mediating outgrowth suppression not defined
    • PROX1 link correlative
  15. 2025 Low

    Documented a context-dependent reversal of PTPRG function, supporting survival of malignant plasma cells in multiple myeloma.

    Evidence siRNA knockdown with viability/apoptosis readouts and scRNA-seq context in MM cell lines

    PMID:41050668

    Open questions at the time
    • Single functional KD experiment without mechanistic detail
    • Molecular basis for the pro-survival switch unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PTPRG's catalytic activity is mechanistically coupled to its diverse roles — contactin adhesion, bicarbonate sensing, and context-dependent tumor suppression versus plasma-cell survival — remains unresolved.
  • No unifying model linking extracellular ligand/sensor inputs to substrate selection
  • Basis of the myeloma-specific pro-survival role uncharacterized in the corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 5 GO:0016787 hydrolase activity 1 GO:0098631 cell adhesion mediator activity 1 GO:0140299 molecular sensor activity 1
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-1643685 Disease 3
Partners
AXLCNTN3CNTN4CNTN5CNTN6EGFRFGFR1VIRMA

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 Crystal structures of the carbonic anhydrase-like domains of PTPRG and PTPRZ revealed that PTPRG directly interacts with the second and third immunoglobulin repeats of contactins CNTN3, CNTN4, CNTN5, and CNTN6 (but not CNTN1, which is specific to PTPRZ). Crystal structure of mouse CNTN4 N-terminal Ig repeats in complex with the carbonic anhydrase-like domain of mouse PTPRG showed CNTN4 adopts a horseshoe-like conformation and contacts a discrete beta-hairpin loop region of PTPRG. X-ray crystallography; direct binding assay; structure of PTPRG carbonic anhydrase-like domain alone and in complex with CNTN4 Proceedings of the National Academy of Sciences of the United States of America High 20133774
2013 Molecular modeling of human contactin 4, 5, and 6 interaction with PTPRG showed that interactive residues between contactin 4-6 and PTPRG are strictly conserved, and no differences in PTPRG binding were observed experimentally among contactin 5 and 6, suggesting differential neurite outgrowth effects of contactins do not result from distinct interactions with PTPRG. 3D structural modeling; co-culture neuritogenesis assay; comparative binding analysis Biology open Medium 23519440
2018 PTPRG interacts with and colocalizes with FGFR1 at the plasma membrane in osteosarcoma cells, and directly dephosphorylates activated FGFR1. Depletion of PTPRG increased FGFR1 activity, hypersensitized cells to FGF1 stimulation, elevated cell growth, and reduced efficacy of FGFR kinase inhibitors. Proximity-dependent biotin labeling (BioID) combined with label-free quantitative mass spectrometry; co-immunoprecipitation; colocalization imaging; PTPRG knockdown with phenotypic readouts; in vitro dephosphorylation assay Molecular & cellular proteomics : MCP High 29371290
2018 PTPRG, restricted to cholesterol-rich lipid domains, dephosphorylates the RTK AXL when AXL is recruited to lipid domains through its interaction with the GPI-anchored tumour suppressor OPCML (which binds activated AXL). This OPCML-PTPRG cooperation prevents AXL-mediated transactivation of cMET and EGFR, inhibits sustained phospho-ERK signalling, reduces EMT transcription factor Slug induction, and suppresses cell migration and invasion in ovarian cancer. Co-immunoprecipitation; lipid domain fractionation; phosphatase activity assay; OPCML/PTPRG functional knockdown; in vitro and in vivo tumor models EMBO reports High 29907679
2015 PTPRG dephosphorylates EGFR at Y1068 and Y1086 in nasopharyngeal carcinoma (NPC) cells, inactivating the PI3K/Akt signaling cascade and downregulating pro-angiogenic and pro-invasive proteins VEGF, IL6, and IL8, thereby suppressing tumor cell proliferation, angiogenesis, and invasion in vitro and in vivo. Co-immunoprecipitation (PTPRG-EGFR interaction); phospho-specific western blot; PTPRG overexpression and Akt knockdown; in vitro and in vivo tumor models Oncotarget Medium 25970784
2010 Overexpression of PTPRG in MCF-7 breast cancer cells inhibited tumor formation in vivo (athymic mouse model), upregulated p21(cip) and p27(kip) cell cycle inhibitors, delayed cell cycle re-entry after serum starvation, and reduced ERK1/2 phosphorylation, indicating PTPRG acts as a tumor suppressor through the ERK1/2 pathway. Xenograft tumor model; western blot for cell cycle regulators; ERK1/2 phosphorylation assay; cell cycle re-entry assay; methylation assay Anticancer research Medium 20651337
2012 PTPRG (RPTPγ) exhibits tyrosine phosphatase activity in vitro; a C1060S catalytic mutant is completely inactive. PTPRG auto-dephosphorylates at Y1307 in its D2 domain, as demonstrated by substrate trapping mutant analysis (C1060S, D1028A) and in vitro dephosphorylation experiments. Loss of PTPRG phosphatase activity (knockdown or catalytically inactive knock-in mice) produces antidepressive-like behavior in mice. In vitro phosphatase activity assay; active-site mutagenesis (C1060S, D1028A); substrate trapping; truncation and mutagenesis mapping; knock-in and knockdown mouse models; behavioral assays PloS one High 23029056
2014 In 293 cells, PTPRG expression induces dephosphorylation of ERK, a downstream RAS target, implicating PTPRG as a direct negative regulator of RAS/ERK signaling. DNA methylation of the PTPRG promoter silences PTPRG expression and cooperates with RAS mutations in childhood ALL oncogenesis; the PTPRG promoter contains a binding site for the RAS-responsive transcription factor RREB1. PTPRG expression in 293 cells with ERK phosphorylation readout; genome-wide methylation profiling; ChIP for RREB1 at PTPRG promoter; correlation of methylation with gene expression International journal of cancer Medium 24496747
2020 RPTPγ (encoded by PTPRG) functions as an HCO3−-sensor in endothelial cells of resistance arteries. Its presence enhances endothelial intracellular Ca2+ responses and facilitates endothelium-dependent vasorelaxation only when CO2/HCO3− is present. RPTPγ limits increases in cerebral perfusion during neuronal activity, amplifies decreases during hyperventilation, and augments hyperventilation-induced blood pressure elevations, without affecting resting blood pressure. Transgenic (knockout) mouse model; Ca2+ imaging in resistance artery endothelial cells; myography for vasorelaxation; cerebral perfusion measurement; blood pressure recording eLife High 32955439
2018 PTPRG expression positively modulates nilotinib response in CML cells and negatively affects BCR-ABL1-dependent transformation. PTPRG knockout by CRISPR/Cas9 in CML cell lines revealed that loss of PTPRG increases BCR-ABL1 signaling events, while overexpression reduces them. CRISPR/Cas9 gene knockout; PTPRG overexpression in CML cell lines; BCR-ABL1 signaling readout; functional nilotinib response assay Oncotarget Medium 29507701
2024 Within neurons, PTPRG physically binds and upregulates the m6A methyltransferase VIRMA, which inhibits translation of PRKN mRNA, thereby suppressing mitophagy and leading to neuronal death in Alzheimer's disease. This interaction was validated by co-immunoprecipitation in mouse brains. Single-cell RNA sequencing; spatial transcriptomics; co-immunoprecipitation in mouse brain; western blot; 5xFAD mouse model Pharmacological research Medium 38325728
2016 miR-19b directly suppresses PTPRG expression by binding two specific sites in the 3'-UTR of PTPRG, leading to increased cell proliferation, stimulated migration, and reduced apoptosis in breast cancer cells. miR-19b overexpression and knockdown in MCF-7 and MDA-231 cells; western blot for PTPRG protein; 3'-UTR luciferase reporter assay; proliferation, migration, and apoptosis assays Oncotarget Medium 27602768
1993 Mouse L-cells (a sarcoma-producing cell line) exhibit homozygous intragenic deletion of the Ptprg gene within the carbonic anhydrase-like domain (exons 2-4 deleted), resulting in a mutant transcript 400 bp shorter than wild type, and loss of one allele—consistent with biallelic inactivation of a tumor suppressor locus. RT-PCR on L-cell mRNA; PCR on genomic DNA; interspecific backcross mapping; sequencing of deletion boundaries Cancer research Medium 8453613
2025 siRNA-mediated knockdown of PTPRG in cultured dorsal root ganglion (DRG) neurons and explants increased neurite outgrowth and enhanced sensory axonal regeneration. RNA sequencing after PTPRG knockdown revealed activation of metabolism-related pathways and altered expression of the transcription factor PROX1, identifying PTPRG as a negative regulator of axonal regeneration. siRNA knockdown; neurite outgrowth and axonal regeneration assays in DRG neurons and explants; RNA sequencing Frontiers in cell and developmental biology Medium 41323734
2010 Methylation of PTPRG intron 1 in colorectal cancer is associated with loss of binding of the insulator protein CTCF to the methylated region, as demonstrated by chromatin immunoprecipitation (ChIP). This methylation does not directly affect PTPRG expression levels but may affect tumor gene expression through CTCF-dependent enhancer blocking or chromosome loop formation. CpG island microarray; bisulfite sequencing; ChIP for CTCF binding European journal of human genetics : EJHG Medium 21150880
2025 In multiple myeloma cell lines (U266 and NCI-H929), siRNA-mediated knockdown of PTPRG reduced cell viability and increased apoptosis, identifying PTPRG as a positive regulator of survival/stemness in malignant plasma cells (in contrast to its tumor suppressor role in solid tumors). siRNA knockdown in MM cell lines; cell viability assay; apoptosis assay; single-cell RNA sequencing for context Frontiers in immunology Low 41050668

Source papers

Stage 0 corpus · 47 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 187 15897551
2010 The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules. Proceedings of the National Academy of Sciences of the United States of America 108 20133774
2016 Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Molecular psychiatry 78 26830138
1996 The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer research 66 8895736
2019 Long noncoding RNA PTPRG-AS1 acts as a microRNA-194-3p sponge to regulate radiosensitivity and metastasis of nasopharyngeal carcinoma cells via PRC1. Journal of cellular physiology 54 30993702
2015 PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma. Oncotarget 43 25970784
2013 Contactin 4, -5 and -6 differentially regulate neuritogenesis while they display identical PTPRG binding sites. Biology open 39 23519440
2019 Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway. Cell proliferation 37 31012177
1993 A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells. Cancer research 37 8453613
1996 Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation. Genomics 35 8833149
2018 Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors. Molecular & cellular proteomics : MCP 31 29371290
2018 The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO reports 30 29907679
2016 MiR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget 27 27602768
2010 Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer research 26 20651337
2024 Single-cell and spatial transcriptomics reveals that PTPRG activates the m6A methyltransferase VIRMA to block mitophagy-mediated neuronal death in Alzheimer's disease. Pharmacological research 23 38325728
2013 Distribution of different isoforms of receptor protein tyrosine phosphatase γ (Ptprg-RPTP γ) in adult mouse brain: upregulation during neuroinflammation. Brain structure & function 21 23536318
2022 A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease. Biomolecules 20 35053232
2014 Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG? Genetics and molecular research : GMR 20 25158255
2020 PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion. eLife 19 32955439
2020 Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4. Technology in cancer research & treatment 19 33174523
2024 POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis. Epigenomics 17 38318853
2010 Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. European journal of human genetics : EJHG 17 21150880
2022 LncRNA PTPRG-AS1 facilitates glycolysis and stemness properties of esophageal squamous cell carcinoma cells through miR-599/PDK1 axis. Journal of gastroenterology and hepatology 16 34676588
2020 Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression. Journal of ovarian research 15 33099316
2013 Association of transcription factor 4 (TCF4) and protein tyrosine phosphatase, receptor type G (PTPRG) with corneal dystrophies in southern Chinese. Ophthalmic genetics 15 23758498
2022 Long non-coding RNA PTPRG-AS1/microRNA-124-3p regulates radiosensitivity of nasopharyngeal carcinoma via the LIM Homeobox 2-dependent Notch pathway through competitive endogenous RNA mechanism. Bioengineered 13 35300558
2018 PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget 13 29507701
2014 Association of common variants in TCF4 and PTPRG with Fuchs' corneal dystrophy: a systematic review and meta-analysis. PloS one 12 25299301
2014 PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia. International journal of cancer 11 24496747
2022 Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Frontiers in oncology 10 35433461
2021 Long Noncoding RNAs PTPRG Antisense RNA 1 Targets Cyclin D1 to Facilitate Cell Proliferation in Lung Adenocarcinoma. Cancer biotherapy & radiopharmaceuticals 9 34767727
2020 Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar. Molecular genetics & genomic medicine 9 32700424
2012 Characterization of PTPRG in knockdown and phosphatase-inactive mutant mice and substrate trapping analysis of PTPRG in mammalian cells. PloS one 8 23029056
2022 Oxidative Phosphorylation-Related Signature Participates in Cancer Development, and PTPRG Overexpression Suppresses the Cancer Progression in Clear Cell Renal Cell Carcinoma. Journal of immunology research 6 36405010
2021 LncRNA PTPRG-AS1 Promotes the Metastasis of Hepatocellular Carcinoma by Enhancing YWHAG. Journal of oncology 5 34876904
2021 Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors. Gene 5 34906644
2025 PTPRG-AS1 regulates the KITLG/KIT pathway through the ceRNA axis to promote the malignant progression of gastric cancer and the intervention effect of Compound Kushen injection on it. Pharmacological research 2 40250508
2024 LncRNA PTPRG-AS1 Promotes Breast Cancer Progression by Modulating the miR-4659a-3p/QPCT Axis. OncoTargets and therapy 2 39380914
2024 Mechanism of HOXA10 in nasopharyngeal carcinoma cell proliferation through the PTPRG-AS1/USP1 axis. Journal of biochemical and molecular toxicology 2 39445487
2019 Retracted Article: Long noncoding RNA PTPRG-AS1 regulates growth of glioma cells by sponging miR-185-5p. RSC advances 2 35515299
2025 miR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer. Translational oncology 1 40561798
2026 Long Non-Coding RNA PTPRG-AS1 Promotes Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer Cells via Modulation of the IGF1/PI3K/AKT Signaling Pathway. Molecular carcinogenesis 0 41911437
2026 Cell-Type-Resolved Pseudobulk Classification Across Independent Cohorts Identifies Microglial PTPRG as a Transcriptional Hub in Alzheimer's Disease. bioRxiv : the preprint server for biology 0 41993387
2025 Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma. Frontiers in immunology 0 41050668
2025 Knocking down tumor suppressor gene PTPRG enhances axonal regeneration of dorsal root ganglion neurons. Frontiers in cell and developmental biology 0 41323734
2021 Retraction: Long noncoding RNA PTPRG-AS1 regulates growth of glioma cells by sponging miR-185-5p. RSC advances 0 35685905
2008 [Methylation of PTPRG gene and its regulation in gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 0 18646686

Missed literature

Know a paper Affinage missed for PTPRG? Flag it for the maintainers and the community.

No submissions yet.